ONCAlert | Upfront Therapy for mRCC
Videos  >  

Overcoming Resistance to PARP Inhibitors in Ovarian Cancer

Shannon N. Westin, MD, MPH
Published Online:6:41 PM, Fri October 26, 2018

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance seen with PARP inhibitors in ovarian cancer and how this resistance can be overcome.

Westin says that she predominantly sees resistance after what she calls the “treatment phase” rather than in patients given PARP inhibitors in the maintenance setting. These patients experiencing resistance often have either germline or somatic BRCA mutations and were treated with single-agent PARP inhibitors in the recurrent setting.

A number of combination strategies are being looked at for overcoming this challenge in ovarian cancer, according to Westin. These combinations include PARP with either different immunotherapies or various pathways that make sense in the patient. This is currently a major area of research.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.